Breast cancer chemotherapy typically involves drugs from two main classes: anthracyclines and taxanes. These are often combined with each other or with a third drug called cyclophosphamide, and the specific combination depends on the cancer’s stage, subtype, and biology. Most people receive chemotherapy in cycles over three to six months, with treatment given every one to three weeks.
The Two Core Drug Classes
Anthracyclines and taxanes form the backbone of breast cancer chemotherapy. They work in different ways, which is why they’re frequently used together or in sequence.
Anthracyclines, including doxorubicin and epirubicin, damage the DNA inside cancer cells to stop them from dividing. These drugs are among the most effective chemotherapy agents for breast cancer but carry a small risk of heart damage, so your oncologist will monitor heart function during treatment. Taxanes, including paclitaxel and docetaxel, work by freezing the internal scaffolding that cells need to divide. Without that scaffolding collapsing and rebuilding properly, cancer cells can’t replicate. Cyclophosphamide, an alkylating agent, is the third drug you’ll see in most regimens. It cross-links DNA strands, making it impossible for the cell to copy its genetic material.
Common Chemotherapy Regimens
Rather than receiving a single drug, most people get a specific combination referred to by its initials. The most widely used regimen for early-stage breast cancer is AC-T: four cycles of doxorubicin plus cyclophosphamide (the “AC” portion), followed by four cycles of a taxane, either paclitaxel or docetaxel (the “T”). This sequential approach has shown better disease-free and overall survival compared with shorter, four-cycle alternatives in trials of node-positive breast cancer.
Other regimens include:
- TC: Docetaxel plus cyclophosphamide, often used for lower-risk cancers where an anthracycline isn’t necessary. This avoids the heart risks associated with doxorubicin.
- TAC: Docetaxel, doxorubicin, and cyclophosphamide given together every three weeks for six cycles. At 10 years of follow-up, this regimen showed a disease-free survival rate of 62%, compared with 55% for a non-taxane version.
- FEC-T: Three cycles of fluorouracil, epirubicin, and cyclophosphamide followed by three cycles of docetaxel. Five-year overall survival with this approach reached about 91%.
- CMF: Cyclophosphamide, methotrexate, and fluorouracil, an older regimen given over six 28-day cycles. It’s less commonly used now but remains an option when anthracyclines and taxanes aren’t suitable.
How Schedules and Cycles Work
A “cycle” means one round of treatment followed by a rest period to let your body recover. Most cycles run every two or three weeks. Docetaxel is typically given every three weeks, while paclitaxel can be given weekly or every two weeks, depending on the regimen. A full course of chemotherapy usually spans 12 to 24 weeks.
Current guidelines generally recommend at least six cycles of adjuvant chemotherapy, though some trial data suggests four cycles may produce equivalent outcomes in certain lower-risk patients. In one large study, four-year relapse-free survival was nearly identical between four and six cycles of the same regimen (91.8% versus 90.9%). Your oncologist will weigh the cancer’s risk profile against the added side effects of longer treatment.
Treatment Varies by Breast Cancer Subtype
Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) lacks the three receptors that other targeted therapies latch onto, making chemotherapy the primary systemic treatment. The standard approach uses anthracyclines and taxanes, but platinum drugs like carboplatin are increasingly added because they directly damage DNA in a way that TNBC cells struggle to repair. Adding a platinum agent to an anthracycline-and-taxane regimen increases the rate of complete pathologic response, meaning no cancer is detectable in the surgical specimen after treatment. This benefit is especially pronounced in patients carrying BRCA1 or BRCA2 gene mutations, whose cancer cells already have a weakened ability to fix DNA damage. Some research also supports paclitaxel plus carboplatin as a standalone alternative to anthracycline-based regimens for operable TNBC.
HER2-Positive Breast Cancer
HER2-positive cancers are treated with chemotherapy paired with targeted antibodies that block the HER2 protein on the cell surface. The most common combination is a taxane given alongside trastuzumab and pertuzumab, two antibodies that attack HER2 from different angles. This dual-blockade approach is approved for use before surgery, after surgery, and for advanced disease. When cancer progresses despite initial treatment, antibody-drug conjugates offer a newer option. These medications attach a chemotherapy payload directly to an antibody, delivering the drug straight into cancer cells while limiting damage to healthy tissue. Five antibody-drug conjugates are now approved for breast cancer, including trastuzumab emtansine and trastuzumab deruxtecan for HER2-positive disease, and sacituzumab govitecan for triple-negative disease.
Before Surgery vs. After Surgery
Chemotherapy given before surgery is called neoadjuvant treatment. Its primary goals are to shrink the tumor enough to allow a less extensive operation and to reveal whether the cancer responds to the chosen drugs. A tumor that disappears completely before surgery is a strong sign that the treatment is working against any microscopic cancer cells elsewhere in the body. If residual cancer remains, oncologists can use that information to switch to a different regimen after surgery.
Chemotherapy given after surgery is called adjuvant treatment. Its goal is to eliminate cancer cells that may have spread beyond the breast before diagnosis but are too small to detect on imaging. Both approaches use the same drugs and regimens. The choice of timing depends on tumor size, lymph node involvement, and subtype. Neoadjuvant therapy is standard for most triple-negative and HER2-positive cancers, while hormone-receptor-positive cancers more commonly receive adjuvant chemotherapy.
Side Effects Across Drug Classes
All chemotherapy drugs affect fast-dividing healthy cells alongside cancer cells, which is why side effects like hair loss, nausea, and fatigue are common. Beyond these universal effects, each drug class carries its own risks. Anthracyclines can damage heart muscle, so cumulative doses are capped and heart function is checked regularly. Taxanes frequently cause peripheral neuropathy: tingling, burning, or numbness in the hands and feet that can persist after treatment ends. When neuropathy develops, your care team will often reduce the dose or adjust the schedule to prevent permanent nerve damage.
Low blood cell counts are one of the most closely monitored side effects. A drop in white blood cells raises infection risk, a drop in red blood cells causes anemia and fatigue, and low platelets can lead to unusual bleeding or bruising. Regular bloodwork between cycles catches these changes early. Signs that need prompt attention include a fever of 100.5°F or higher, diarrhea lasting more than two days, and unexplained bleeding or bruising anywhere on the body.
Platinum drugs, when added for triple-negative breast cancer, increase the overall toxicity of the regimen. Nausea, kidney stress, and deeper drops in blood counts are more common with platinum-containing combinations, which is why they’re reserved for subtypes where the benefit clearly outweighs the added burden.